<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011774</url>
  </required_header>
  <id_info>
    <org_study_id>D17-P025</org_study_id>
    <nct_id>NCT04011774</nct_id>
  </id_info>
  <brief_title>Planning Your Everyday Life in Virtual Reality : a Study in Schizophrenia;</brief_title>
  <acronym>PlaniRev</acronym>
  <official_title>PLANning Your Every Day Life I Virtual REality : a Study Schizophrenia. Mathurin Serious Game</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier St Anne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with schizophrenia , who visit frenquently day-care or day-care activities clinics,
      often experience difficulties of daily living and cognitive deficits. Living independently is
      a key for recovery. Cognitive remediation is a therapy which reduces deficit and improves
      daily living. Nowadays no program exists targeting neurocognitive functions in virtual
      reality which could mimic everyday life in a virtual town.

      Hypotheses :

        -  Persons with schizophrenia experience difficulties in daily living and disabilities to
           plan in everyday life. PLANI-REV program, a serious game with a navigation in a virtual
           town, in a 15 weekly group sessions could reduce these difficulties compared to the
           initial assessment. This improvement could be maintained 6 months after the end of the
           program.

        -  PLANI-REV could also improve prospective memory, attention, working memory, and
           visuospatial organization.

        -  PLANI-REV could induce a clinical improvement, as well as better perception of
           self-efficiency, self esteem, quality of life, and conversation skills.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PLANI-REV : questionnaire scores</measure>
    <time_frame>10 months</time_frame>
    <description>the comparison pre/post PLANI-REV of the number of difficulties of daily life using the Profinteg questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Profinteg scores 6 months after PLANI-REV. Number of problematic activities; average score for difficulties of problematic activities.</measure>
    <time_frame>16 months</time_frame>
    <description>To improve pre/post PLANI-REV and 6 months after, neuropsychological performances in prospective memory, attention, working memory, executive functions, and visual and spatial organization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PLANI-REV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RELAXATION</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLANI-REV</intervention_name>
    <description>Cognitive remediation program.</description>
    <arm_group_label>PLANI-REV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RELAXATION</intervention_name>
    <description>Stimulation with no cognitive remediation.</description>
    <arm_group_label>RELAXATION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years old.

          -  Diagnostic of schizophrenia or schizoaffective disorder (DSM V), attested by the MINI
             structured interview (Shehan et al. 1998)

          -  Who visit for months or year, weekly or several times per week, a day care, or
             therapeutic activity units outpatients clinics and nursing homes

          -  French Mother tongue

          -  Consent of the legal representative caregiver for the patients under representative
             law (tutelle in French).

          -  Clinical Stability - Therapeutic stability for at least one month.

          -  National healthcare assurance

        Exclusion Criteria:

          -  Central Neurological or non stabilized somatic diseases.

          -  Treatments for somatic disease with putative psychotropic effect.

          -  Electroconvulsive therapy in the last six months

          -  Illetrism

          -  IQ&lt; 70 established with the f-NART.

          -  Substance misuse or dependence (except Nicotine) or toxic for more than 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle AMADO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHSA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle AMADO, MD</last_name>
    <phone>+33 1 45 65 81 80</phone>
    <email>i.amado@ch-sainte-anne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie DOROCANT</last_name>
    <phone>+33 1 45 65 77 28</phone>
    <email>s.dorocant@ch-sainte-anne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier DURANT</name>
      <address>
        <city>Etampes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François PETITJEAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital les Murets</name>
      <address>
        <city>La Queue-en-Brie</city>
        <zip>94510</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier QUENZER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle AMADO, MD</last_name>
      <email>i.amado@ch-sainte-anne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie DOROCANT</last_name>
      <email>s.dorocant@ch-sainte-anne.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Guillaume Régnier</name>
      <address>
        <city>Rennes</city>
        <zip>35703</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David LEVOYER, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

